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Abstract
Background: Myrtus communis L. has a folkloric repute for the management of diarrhea and dysentery in different
parts of the world. However, the safety and efficacy of the leaf extract have not been scientifically validated in
animal model. This study was, therefore, aimed to investigate the antidiarrheal effect of 80% methanol extract
(80ME) and solvent fractions of the leaves of Myrtus communis L. in mice.
Methods: The antidiarrheal activity of the 80ME and solvent fractions was evaluated against castor oil induced
diarrheal model, charcoal meal and enteropooling tests. For the 80%ME, the test groups received 100, 200 and
400 mg/kg of the extract. In case of fractions, the test groups received various doses of fractions (200, 300,
400 mg/kg and an additional dose of 800 mg/kg for the aqueous fraction (AF)), where as negative controls
received the vehicle (10 ml/kg) and positive controls received loperamide (3 mg/kg).
Results: The 80ME at 200 mg/kg (p < 0.05) & 400 mg/kg (p < 0.01) as well as the chloroform fraction (CF) and
methanol fraction (MF) at 400 mg/kg (p < 0.05) significantly delayed the onset of diarrhea. Besides, the 80ME
(at all tested doses) and both of these fractions (at 300 & 400 mg/kg) significantly decreased the frequency and
weight of fecal outputs. Results from the charcoal meal test revealed that the 80ME, at all doses, (p < 0.001)
as well as the CF and MF at 300 mg/kg (p < 0.05) & 400 mg/kg (p < 0.001) produced a significant anti-motility
effect. Similarly, in the entero-pooling test, the 80ME (at all tested doses) (p < 0.01) as well as the CF and MF
(at 300 & 400 mg/kg, p < 0.05) produced a significant decline in the weight and volume of intestinal contents,
whereas the AF revealed significant effect (p < 0.05) at dose of 800 mg/kg only.
Conclusion: The study demonstrated that the 80ME and solvent fractions contain bioactive constituents that
have antidiarrheal activity. Therefore, this study provides a scientific support for the acclaimed traditional use of
Myrtus communis L for the treatment of diarrheal diseases.
Keywords: Myrtus communis, Castor oil, Antidiarrheal activity, 80%ME, Solvent fractions
Background
Since the time immemorial, medicinal plants have
played an invaluable role in the development of thera-
peutic agents. Currently, it is estimated that about 80%
of people living in developing countries still rely on
traditional medicine for their primary health care [1].
There are many medicinal plants that possess antidiar-
rheal activity with lesser side effects than the conventional
drugs. Tannins, alkaloids, flavonoids and terpenoids are
the major constituents that are primarily responsible for
antidiarrheal activity of these medicinal herbs [2]. In
Ethiopia, a range of medicinal plants have been widely
used for the management of diarrhea and related gastro-
intestinal disorders by traditional healers [3–5]. However,
the safety and therapeutic potentials of some of these me-
dicinal plants have not been validated yet. Among them,
Myrtus communis L. is one of the popular medicinal
plants being used in the traditional medicine.
Myrtus communis L. (Myrtaceae) is the only species of
the genus found in the Northern Hemisphere. It is an
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aromatic evergreen perennial shrub native to Southern
Europe, North Africa and West Asia. Myrtus, the Greek
name for Myrtle and communis means a common plant
growing in groups [6–8]. In Ethiopia, it has several ver-
nacular names such as Ades (Amharic, Guragegna,
Tigregna); Haddus (hararegna), Addisaa, coddoo (Afan
Oromo) [9]. It is one of the most important drugs being
used in Unani system of medicine since ancient Greece.
It is a well-known shrub for its therapeutic, cosmetic
and food uses [8]. It has also been frequently used for
various ailments like gastric ulcer, diarrhea, dysentery
and rheumatism [8].
Moreover, the leaves of Myrtus communis L. are
traditionally used for abdominal pain and diarrhea in
Pakistanian and Indian traditional medicines [10], in
Turkish traditional medicine (the leaves are boiled and
the stock is drunk) [11] and in Iranian traditional
medicine [12]. In Ethiopia, It has been used as antipyr-
etic and sedative agent [13], anti-dandruff (bathing
with crushed fresh leaves) [5], antidiarrheal and stom-
achic (the leaves are soaked with water overnight and
the juice is taken orally in the morning) [5]. Previous
in vitro study on isolated tissue preparations demon-
strated that 70% methanolic extract of the leaves of
Myrtus communis L. revealed antispasmodic, broncho-
dilator and vasodilator activities [14]. Besides, the es-
sential oil of Myrtus communis L. (myrtle oil) also
possessed significant antidiarrheal activity both in vivo
and ex-vivo [15]. Therefore, extensive folkloric uses
and previous studies were used as a baseline data to
validate the antidiarrheal activity of the leaf extracts of
Myrtus communis L. in mice.
Methods
Drugs and chemicals
All solvents used for the extraction process are of la-
boratory grade. Drugs and chemicals used in the study
include: castor oil (Amman Pharmaceutical Industries,
Jordan), activated charcoal (Acuro Organics Ltd, New
Delhi, India), Loperamide (Daehwa Pharmaceuticals,
Republic of Korea), distilled water (Ethiopian Pharma-
ceutical Manufacturing Factory, Epharm, Ethiopia),
Tweens 80 (Atlas Chemical Industries Inc, India),
chloroform (Hi-Media Laboratory Reagents, India), abso-
lute methanol (Carlo Erba reagents, S.A.S., France), glacial
acetic acid (BDH Laboratory Supplies Poole, England), sul-
furic acid (BDH Laboratory Supplies Poole, England),
ammonia(BDH Limited poole, England), hydrochloric
acid(BDH Laboratory Supplies Poole, England), acetic
anhydride (May and Baker LTD Dagenham, England),
ferric chloride (BDH Laboratory Supplies Poole,
England), Mayer’s and Dragendorff ’s reagents(May
and Baker LTD Dagenham, England).
The plant material
The leaves of Myrtus communis L. were collected from
Mersa town, North Wollo zone, Amhara region
(490 km northeast of Addis Ababa) in October, 2014.
The plant was authenticated by a taxonomist and a
voucher specimen (number MS 002) was deposited at
the National Herbarium, College of Natural and Com-
putational Sciences, Addis Ababa University (AAU) for
future reference. The leaves were washed gently and
dried at room temperature under shade for 2 weeks.
The dried leaves were then reduced to appropriate size
using mortar and pestle.
Experimental animals
Swiss albino mice of either sex weighing 20–30 g and
aged 6–8 weeks were used for the experiment. The mice
were obtained from animal house of School of Phar-
macy, AAU and Ethiopian Public Health Institute
(EPHI). The animals were kept in plastic cages at room
temperature and on a 12 h light/dark cycle with access
to pellet food and water ad libitum. The mice were accli-
matized to laboratory condition for 1 week prior to the
experiment. Food was withdrawn 18 h prior to the be-
ginning of all the experiments. However, water was
accessed except in entero-pooling, where both food and
water were withdrawn. The care and handling was ac-
cording to international guidelines for the use and main-
tenance of experimental animals [16, 17].
Extraction of the plant material
Preparation of 80ME
Hundred fifty gram of the dried powder was weighed
using a digital balance and added to an Erlenmeyer flask
to which 500 ml of 80ME solvent was poured in the first
round. The plant material was macerated for 72 h with
occasional shaking using mini-orbital shaker (Bibby sci-
entific limited stone Staffordshire, SI150SA, UK) at
120 rpm. The extract was filtered through double lay-
ered muslin cloth followed by Whatman No.1 filter
paper (Schleicher and Schuell Micro science Gmbh,
Germany). The marc was then re-macerated for a second
and third time by adding another fresh solvent. The result-
ant filtrates were combined and concentrated using a ro-
tary evaporator (Buchi labortechnik AG, Switzerland)
under reduced pressure at 40 °C. A dark green paste was
obtained and kept into a deep freezer (AFTRON AFF 545,
Denmark) to solidify. The residual aqueous solvent was
then removed using a lyophilizer (Operon, Korea
vacuum limited, Korea). The percentage yield of 80ME
was then found to be 16.33% (w/w). Finally, the ex-
tract was kept in deep freeze with an air tight con-
tainer until the experiment.
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Preparation of solvent fractions
Both Soxhlet and maceration techniques were used for
extraction of the plant material. The initial procedure
closely resembles to that of the 80ME. However, the
dried leaves were pulverized to coarse powder using
mortar and pestle and then sieved to maintain uniform-
ity of particle size. From this, 150 g dry powder was sub-
jected to successive soxhlet extraction with solvents of
increasing polarity (chloroform and absolute methanol)
followed by maceration of the marc of methanol with
distilled water.
In every batch, 50 g of the powdered plant material
was added into the extraction thimble which was then
placed into the chamber of the Soxhlet apparatus. First,
350 ml chloroform was added into the bottom flask that
had been fixed with Soxhlet apparatus and heat was ap-
plied until clear liquid contents of the chamber siphoned
into the solvent. The CF was then subjected to filtration
with suction filter. Besides, it was concentrated using ro-
tary evaporator under reduced pressure set at 40 °C
followed by dried with oven at room temperature for
48 h. The marc (in the thimble) was collected and then
dried overnight at room temperature to remove chloro-
form. The dried marc was re-extracted using absolute
methanol using the same procedure as described for the
CF except that the MF was kept for a week in an oven at
room temperature. Besides, the marc of MF was then
collected and dried at room temperature overnight.
Finally, the dried marc of methanol was combined
from every batch and macerated in an Erlenmeyer
flask with distilled water and allowed to stand at room
temperature for a period of 3 days in each round
(total of 9 days) with occasional shaking using mini-
orbital shaker. The procedure utilized for extraction
of 80ME was repeated except that lyophilization in-
stead of vaporization was used directly to concentrate
the extract. After drying, the percentage yields of all
fractions were determined and found to be 5.2, 13.8
and 7.2% for the CF, MF and AF, respectively. The
fractions were kept in deep freeze with air tight con-
tainers till use.
Acute oral toxicity test
According to the Organization for Economic Cooper-
ation and Development (OECD) guidelines 2008: 425, a
single female mouse was fasted for 3 h and was loaded
with 2000 mg/kg of the 80ME as a single dose by oral
gavage. It was then observed for any sign of toxicity
within the first 24 h. Based on the results of the first
mouse; another 4 female mice were recruited and fasted
for 3 h. Thereafter, they were given the same dose and
observed for any sign of toxicity or death in the next
14 days [18].
Grouping and dosing
Mice were randomly assigned into five groups of six ani-
mals each for both 80ME and solvent fractions. All
groups received their respective treatments using oral
gavage. The first group was assigned as negative control
and received a vehicle (distilled water for 80ME, MF and
AF and 2% tweens-80 for the CF) at 10 ml/kg. The sec-
ond group was assigned as positive control and received
the standard drug, loperamide (3 mg/kg). For the 80ME,
the dose levels of test groups were determined based on
the acute toxicity test [18] and they are treated with
100 mg/kg, 200 mg/kg and 400 mg/kg of 80ME. Com-
ing to the solvent fractions, however, the doses of test
groups were determined based on series of pilot stud-
ies and hence test groups were treated with various
doses of the fractions (200 mg/kg, 300 mg/kg and
400 mg/kg and an additional dose of 800 mg/kg for the
AF). The 80ME and solvent fractions were reconsti-
tuted with the respective vehicles at appropriate con-
centrations. The solutions were prepared fresh on the
day of the experiments.
Determination of antidiarrheal activity
Castor oil (CO) induced diarrhea
The method followed by Umer et al. was used for this
study [19]. Swiss albino mice of either sex were fasted
for 18 h, randomly allocated to five groups of six animals
each and treated as described previously. One hour after
administration of the respective doses and treatments,
all animals received 0.5 ml of CO. Thereafter, they were
individually placed in cages where the floor was lined
with white paper. During an observation period of 4 h,
the onset of diarrhea, frequency of defecation and the
weight of fecal output (wet and total feces in gram) were
recorded for individual mouse. The percentages of diar-
rheal inhibition and weight of fecal output were deter-
mined according to the formulae 1–3 [20, 21].
% of inhibition ¼ Average number of WFC−Average number of WFT
Average number of WFC
X 100
ð1Þ
Where, WFC = wet feces in the control; WFT = wet feces
in the test group.
Percentage of wetfecal output ¼ Mean weight of wetfeces of each group
Mean weight of wet feces of control
X100
ð2Þ
Percentage of totalfecal output ¼ Mean weight of total feces of each group
Mean weight of total feces of control
X100
ð3Þ
CO induced gastrointestinal motility
All mice were fasted for 18 h, divided into five groups of
six animals each and treated as described earlier. An
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hour later, 0.5 ml CO was administered. Then, 1 ml of
marker (5% activated charcoal suspension in distilled
water) was administered orally 1 h after CO treatment.
The animals were then sacrificed after an hour and the
small intestine was dissected out from pylorus to cecum.
The distance travelled by the charcoal meal from the
pylorus was measured and expressed as percentage of
the total length of the small intestine from the pylorus
to cecum (peristaltic index) as shown in formula 4. The
percentage of inhibition was then expressed using the
formula 5 [22].
Peristaltic index PIð Þ ¼ distance travelled by charcoal meal
whole length of small intestine
X 100
ð4Þ
% inhibition ¼ PIC−PIT
PIC
X 100 ð5Þ
Where, PIC = peristaltic index of control; PIT = peristal-
tic index of test group
CO induced enteropooling activity
Intraluminal fluid accumulation was determined using
the method described by Islam et al. [23]. Mice of either
sex were deprived of both food and water for 18 h and
treated as described in grouping and dosing section just
one hour prior to oral administration of 0.5 ml CO. An
hour after CO administration, the mice were sacrificed
by cervical dislocation. The abdomen of each mouse was
opened; the small intestine was then taken from the pyl-
oric sphincter to ileo-caecal junction; ligated at both
ends and dissected out carefully. Each small intestine
was weighed and its content was then collected by gentle
milking into a graduated tube and hence the volume of
intestinal contents was measured. Each intestine was
reweighed and the difference between the full and the
empty intestines was calculated. Eventually, the percent-
age inhibitions of the volume and weight of intestinal
contents were determined according to the formulae 6
and 7, respectively [24].
Percentage of inhibition ¼ MVICC−MVICT
MVICC
X 100 ð6Þ
Where, MVICC =Mean volume of the intestinal con-
tent of the control group; MVICT =Mean volume of the
intestinal content of the test group.




Where, MWICC =Mean weight of the intestinal content
of the control group; MWICT =Mean weight of the in-
testinal content of the test group.
The in vivo anti-diarrheal index
The in vivo antidiarrheal index (ADI) for the 80ME,
solvent fractions and standard drug were determined by
the following formula [25].
In vivo anti diarrheal index ADIð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Dfreq x Gmeq x Pfreq3
p
Where: Dfreq = Delay in defecation time or diarrheal on-
set (in % of control); Gmeq = Gut meal travel reduction
(in % of control) and Pfreq = purging frequency as the
number of wet stool reduction (in % of control).
Preliminary phytochemical screening
The 80ME and solvent fractions were tested for the
presence of alkaloids, flavonoids, tannins, terpenoids,
steroids, glycosides and saponines using standard chem-
ical tests [26].
Statistical analysis
Data are expressed as mean ± standard error of the mean
(SEM). The data were analyzed using SPSS version 16.
Statistical significance was determined by one way ana-
lysis of variance (ANOVA) followed by Tukey post Hoc
test. P-value of less than 0.05 was considered statistically
significant. When appropriate, linear regression analysis
was also applied to observe the dose dependency nature
of antidiarrheal effect.
Results
Acute oral toxicity test
The 80ME of Myrtus communis leaf produced neither
overt toxicity nor death during the 14 days observation
period following oral administration of a single dose of
2000 mg/kg. The absence of mortality and signs of overt
toxicity up to 5 times the maximum effective dose of the
extract suggested that 80ME has a wider safety margin
and LD50 value greater than 2000 mg/kg in mice.
Effects on castor oil induced diarrheal model
In the CO-induced diarrheal model, the 80ME of Myrtus
communis leaf significantly prolonged the onset of diar-
rhea and reduced the frequency and weight of fecal out-
puts at doses of 200 mg/kg and 400 mg/kg as compared
to the control. The 100 mg/kg of the extract, however,
showed a statistically significant effect on frequency of
wet feces (p < 0.001), weight of wet (p < 0.001) and total
(p < 0.05) fecal outputs. Besides, the data revealed that
the percentage of diarrheal inhibitions were 42.58% (p <
0.01), 62.52% (p < 0.001), and 74.96% (p < 0.001) at the
doses of 100 mg/kg, 200 mg/kg, and 400 mg/kg, respect-
ively (Table 1).
Coming to solvent fractions, both CF and MF pro-
duced a significant delay in initiation of diarrhea at
400 mg/kg (p < 0.05). The percentage of diarrheal
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inhibitions obtained as compared to control were
51.23% (p < 0.05) and 58.92% (p < 0.05) at 300 mg/kg
and 400 mg/kg CF, respectively. The CF also showed a
significant reduction in weight of both wet and total
fecal outputs at 300 mg/kg (p < 0.05) and 400 mg/kg
(p < 0.05). Similarly, the MF significantly decreased
the frequency and weight of wet feces at doses of
300 mg/kg (p < 0.05; p < 0.05) and 400 mg/kg (p <
0.05; p < 0.01), respectively with the highest percent-
age of diarrheal inhibition (62.67%, p <0.05) obtained
at 400 mg/kg. On the contrary, the AF was devoid of
any significant delay in onset of diarrhea at all tested
doses as compared with control (Table 1).
There was a dose-dependent reduction in the per-
centage of weight of wet and total fecal outputs in
80ME and solvent fractions with 400 mg/kg of the
80ME displaying the highest effect (22.22 and 27.03%).
Besides, both the CF and MF revealed a moderate re-
duction in the percentage of both fecal outputs with
400 mg/kg MF showing the utmost effect among the
solvent fractions (Table 1).
Effects on castor oil induced intestinal transit in mice
The 80ME significantly inhibited the intestinal transit of
charcoal meal at all tested doses. The data revealed that
the percentage reduction of gastrointestinal transit of
charcoal was 33.54% (p < 0.001), 46.12% (p < 0.001), and
62.31% (p <0.001) at doses of 100 mg/kg, 200 mg/kg,
and 400 mg/kg, respectively. The maximum dose of this
extract showed comparable anti-motility effects to that
of the standard (59.61%, p < 0.001).
The CF and MF also significantly inhibited the intes-
tinal transit of charcoal meal at doses of 300 mg/kg and
400 mg/kg compared to the control with the highest in-
hibitory effect observed at later dose of MF (47.54%, p <
0.001). On the contrary, the AF showed a significant
antimotility effect at the dose of 800 mg/kg (38.61%, p <
0.01) compared to the control (Table 2).
Effects on castor oil induced enteropooling
In this test, the 80ME showed a significant reduction in
both the average volume and weight of intestinal con-
tents (AVIC and AWIC) at all tested doses as compared


















Control 76.67 ± 7.99 6.67 ± 0.49 7.00 ± 0.52 0.36 ± 0.02 0.37 ± 0.02 ————— ——— ——
80ME 100 109.67 ± 12.15 3.83 ± 0.70a2b1f1 4.50 ± 0.72b1f1 0.20 ± 0.02a2b2f2 0.21 ± 0.02a1b1f1 42.58 55.56 56.76
80ME 200 145.00 ± 21.77a1 2.50 ± 0.50a3 3.00 ± 0.68a2 0.14 ± 0.03a3 0.15 ± 0.03a2 62.52 38.89 40.54
80ME 400 173.83 ± 18.03a2 1.67 ± 0.49a3 2.67 ± 0.72a2 0.08 ± 0.02a3 0.10 ± 0.03a3 74.96 22.22 27.03
Loperamide 3 161.50 ± 16.93a2 1.83 ± 0.40a3 2.83 ± 0.60a2 0.09 ± 0.02a3 0.11 ± 0.02a3 72.56 25.00 29.73
Control 80.17 ± 4.34 6.50 ± 0.43 6.83 ± 0.54 0.35 ± 0.03 0.36 ± 0.04 ——— ——— ——
CF 200 123.33 ± 23.81 4.00 ± 1.00 4.33 ± 1.08 0.20 ± 0.05 0.21 ± 0.06 38.46 57.14 58.33
CF 300 140.50 ± 19.99 3.17 ± 0.65a1 3.67 ± 0.76 0.16 ± 0.03a1 0.17 ± 0.04a1 51.23 45.71 47.22
CF 400 152.00 ± 21.01a1 2.67 ± 0.76a1 3.17 ± 0.83a1 0.13 ± 0.04a1 0.15 ± 0.04a1 58.92 37.14 41.67
Loperamide 3 165.83 ± 33.17a1 1.67 ± 0.76a2 2.33 ± 1.05a1 0.08 ± 0.04a2 0.09 ± 0.04a2 74.31 22.86 25.00
Control 69.33 ± 8.98 7.50 ± 1.34 8.17 ± 1.28 0.42 ± 0.05 0.45 ± 0.05 ———— ——— —
MF 200 104.33 ± 6.14 5.17 ± 0.40b1 5.67 ± 0.49b1 0.29 ± 0.03b1 0.30 ± 0.04b1 31.07 69.05 66.67
MF 300 136.00 ± 29.02 3.83 ± 0.87a1 4.33 ± 1.05 0.22 ± 0.06a1 0.24 ± 0.06a1 48.93 52.38 53.33
MF 400 155.50 ± 26.89a1 2.83 ± 0.95a1 3.50 ± 1.23a1 0.14 ± 0.06a2 0.17 ± 0.06a2 62.67 33.33 37.78
Loperamide 3 166.83 ± 25.23a1 1.83 ± 0.70a2 2.33 ± 0.92a2 0.09 ± 0.03a3 0.11 ± 0.04a3 75.56 21.43 24.44
Control 69.33 ± 8.98 7.50 ± 1.34 8.17 ± 1.28 0.42 ± 0.05 0.45 ± 0.05 ———— —— —
AF 200 70.83 ± 6.53b2j1n1 6.83 ± 0.70b2i1j1m1n1 7.67 ± 0.67b2g1i1j1n1 0.39 ± 0.02b3g2i2j2n2 0.42 ± 0.02b3g2i1j2n2 8.93 92.86 93.33
AF 300 77.67 ± 4.86b1j1n1 6.33 ± 0.72b2j1n1 6.67 ± 0.76b1j1n1 0.35 ± 0.03b2g1i1j1n1 0.36 ± 0.04b2i1j1n1 15.60 83.33 80.00
AF 400 81.00 ± 3.53b1 5.67 ± 0.62b1j1n1 6.50 ± 0.62b1j1 0.32 ± 0.02b2j1n1 0.33 ± 0.02b1j1n1 24.40 76.19 73.33
AF 800 134.67 ± 32.67 3.50 ± 0.99a1 4.33 ± 1.22a1 0.18 ± 0.05a2 0.21 ± 0.05a2 53.33 42.86 46.67
Loperamide 3 166.83 ± 25.23a1 1.83 ± 0.70a2 2.33 ± 0.92a2 0.09 ± 0.03a3 0.11 ± 0.04a3 75.56 21.43 24.44
Values are mean ± SEM (n = 6); analysis was performed using one way ANOVA followed by Tuckey post hoc test; a compared with control values; b compared with
loperamide; c compared with 100 mg/kg; d compared with 200 mg/kg; ecompared with 300 mg/kg; f compared with 400 mg/kg; g compared with 800 mg/kg; h
compared with CF200; i compared with CF300; j compared with CF400; kcompared with MF200; m compared with MF 300; ncompared with MF 400; 1p < 0.05, 2p <
0.01, 3p < 0.001; 80ME =80% methanol extract, CF = chloroform fraction, MF =methanol fraction, AF = aqueous fraction. Controls received 10 ml/kg- distilled water
(for 80ME, MF and AF) and 2% Tween-80 (for CF). WWFO =Weight of wet fecal output, WTFO = weight of total fecal output
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to control. The percentage inhibition of volume of intes-
tinal contents was found to be 25.58% (p < 0.01), 38.37%
(p < 0.001), and 46.51% (p < 0.001) at doses of 100 mg/
kg, 200 mg/kg, 400 mg/kg, respectively.
The CF and MF reduced both AVIC and AWIC sig-
nificantly at doses of 300 mg/kg and 400 mg/kg. Max-
imal inhibition of the AVIC was observed at 400 mg/kg,
being 38.46% (p < 0.01) and 40.96% (p < 0.01) for CF and
MF, respectively. On the contrary, the AF was devoid of
any significant inhibitory effect on the AVIC and AWIC
up to 400 mg/kg as compared to control (Table 3).
The in vivo antidiarrheal index
The in vivo antidiarrheal index (ADI) was measured by
considering the delay in defecation (time of onset,
Dfreq), gut meal travel distance (Gmeq) and purging fre-
quency in number of wet stools as major parameters.
The greatest ADI was achieved at the dose of 400 mg/kg
of 80ME (83.96%). Among the solvent fractions, MF
showed the highest ADI value (71.81%) at doses of
400 mg/kg (Table 4).
Preliminary phytochemical screening
The preliminary phytochemical screening of the 80ME
of Myrtus communis leaf revealed the presence of terpe-
noids, flavonoids, tannins, glycosides and saponins but
alkaloids and steroids are lacking. Coming to the solvent
fractions, the data revealed that alkaloids were not de-
tected in all solvent fractions and trace amounts of ste-
roids were detected in the CF. Besides, terpenoids and
flavonoids were detected in both CF and MF. Tannins
were common across all fractions. Glycosides and sapo-
nins were also observed in both MF and AF. Amongst
all, the 80ME and the MF appeared to be relatively rich
in secondary metabolites (Table 5).
Discussion
Medicinal plants have been used for the treatment of
various disorders including diarrhea and related gastro-
intestinal disorders despite the fact that their safety and
efficacy profiles have not been well addressed. It is,
therefore, important to properly evaluate the safety and
efficacy profile of medicinal plants that are being used in
traditional medicines. The need for newer, more
Table 2 Effects of 80ME and solvent fractions of the leaves of Myrtus communis L on gastrointestinal transit in mice
Dose (mg/kg) Length of small
intestine (cm)
Distance moved by the
charcoal meal (cm)
Peristaltic index (%) % inhibition
Control 56.17 ± 1.42 36.67 ± 1.94 65.09 ± 2.25 —————
80ME 100 58.33 ± 0.80 25.17 ± 2.43a3b2f2 43.26 ± 4.37a3b2f2 33.54
80ME 200 58.67 ± 1.12 20.05 ± 1.09a3 35.07 ± 2.27a3 46.12
80ME 400 58.17 ± 2.01 14.33 ± 1.65a3 24.53 ± 2.53a3 62.31
Loperamide 3 56.33 ± 1.28 14.83 ± 0.91a3 26.29 ± 1.34a3 59.61
Control 57.67 ± 1.76 36.17 ± 4.18 62.33 ± 6.06 ————
CF 200 56.33 ± 1.08 25.17 ± 3.46b1 44.88 ± 6.39b1 27.99
CF 300 59.50 ± 1.09 24.00 ± 1.39a1 40.44 ± 2.60a1 35.11
CF 400 60.17 ± 1.89 20.67 ± 2.43a2 34.37 ± 3.91a2 44.86
Loperamide 3 56.83 ± 1.11 14.00 ± 1.41a3 24.58 ± 2.32a3 60.56
Control 58.50 ± 0.67 36.83 ± 3.21 62.81 ± 5.11 —————
MF 200 59.17 ± 1.38 29.17 ± 1.96b2 49.47 ± 3.47b2 21.24
MF 300 59.50 ± 1.41 24.00 ± 3.33a1 40.29 ± 5.48a1 35.85
MF 400 59.00 ± 1.59 19.17 ± 3.27a3 32.95 ± 5.99a3 47.54
Loperamide 3 56.33 ± 1.28 13.67 ± 1.52a3 24.20 ± 2.55a3 61.47
Control 58.50 ± 0.67 36.83 ± 3.21 62.81 ± 5.11 ————
AF 200 56.83 ± 0.95 34.00 ± 1.83b3g1j1n1 59.79 ± 2.98b3g1j1n2 4.81
AF 300 56.83 ± 1.92 31.00 ± 2.05b2g1 54.91 ± 4.33b2g1n1 12.58
AF 400 59.17 ± 0.98 29.50 ± 3.09b2 49.79 ± 4.95b2 20.73
AF 800 56.83 ± 1.17 21.83 ± 3.55a2 38.56 ± 6.29a2 38.61
Loperamide 3 56.33 ± 1.28 13.67 ± 1.52a3 24.20 ± 2.55a3 61.47
Values are mean ± SEM (n = 6); analysis was performed using one way ANOVA followed by Tuckey post hoc test; a compared with control values; b compared with
loperamide; c compared with 100 mg/kg; d compared with 200 mg/kg; ecompared with 300 mg/kg; f compared with 400 mg/kg; g compared with 800 mg/kg; h
compared with CF200; i compared with CF300; j compared with CF400; kcompared with MF200; m compared with MF 300; n compared with MF 400; 1p < 0.05,
2p < 0.01, 3p < 0.001; 80ME = 80% methanol extract, CF = chloroform fraction, MF =methanol fraction, AF = aqueous fraction. Controls received 10 ml/kg- distilled
water (for 80ME, MF and AF) and 2% Tween-80 (for CF)
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effective, cheaper and safer antidiarrheal drugs has be-
come a paramount concern to have safe and cost effect-
ive therapeutic alternatives [2, 27]. This study was aimed
to evaluate the safety and effectiveness of Myrtus com-
munis L. as antidiarrheal agent.
Hydroalcoholic solvent mixtures are generally consid-
ered to give high extraction yields, owing to their ex-
panded polarity index [28]. In general, hydroalcoholic
co-solvents such as 80% methanol seem to possess the
optimum solubility characteristics for initial crude ex-
traction. Hence, 80% methanol was used as solvent of
choice in the present study for extracting the Myrtus
communis L. leaf. Besides, the dry leaf powder was re-
subjected for fractionation with solvents of increasing
polarity to get an idea about the polarity of antidiarrheal
constituents of the plant.
The acute toxicity profile of the leaf extract was deter-
mined based on OECD guideline 2008:425 [18]. On this
test, the LD50 was found to be > 2000 mg/kg for the
80ME. Generally, if the LD50 value of the test chemical
is more than 3 times the minimum effective dose, the
substance is considered as a good candidate for further
studies [29]. Since the hydroalcoholic extract had a LD50
value of more than three times of the minimum effective
dose (100 mg/kg), it was taken as a good candidate for
further studies. Beyond its role for dose determination,
LD50 can also be used for classification of chemicals.
According to WHO hazard classification systems, the
80ME of the leaves of Myrtus communis L. with LD50 >
2000 mg/kg is designated as ‘unlikely to be hazardous’
[30]. Hence, based on the safety profile of the this ex-
tract and prior absence of any toxicity data regarding the
plant, further toxicity studies were not done on the solv-
ent fractions.
Diarrhea occurs when there is an imbalance between
the secretary and absorptive processes of gastrointes-
tinal tract and/or an alteration of motility of intestinal
smooth muscles [31]. The use of CO as diarrhea
inducer has been well documented [25, 32]. When ad-
ministered orally, it produces irritant laxative effect
mediated by its active metabolite, ricinoleic acid re-
leased by intestinal lipases. Ricinoleic acid produces
local irritation and inflammation of the intestinal mucosa,
causing the release of prostaglandins that eventually
Table 3 Effects of 80ME and solvent fractions of the leaves of Myrtus communis L on gastrointestinal fluid accumulation in mice
Dose (mg/kg) Volume of intestinal contents (ml) % inhibition Weight of intestinal contents (gm) % inhibition
Control 0.86 ± 0.07 ————— 1.12 ± 0.03 —————
80ME 100 0.64 ± 0.04a2b1f1 25.58 0.91 ± 0.05a2b1f1 18.75
80ME 200 0.53 ± 0.03a3 38.37 0.77 ± 0.06a3 31.25
80ME 400 0.46 ± 0.02a3 46.51 0.70 ± 0.02a3 37.50
Loperamide 3 0.47 ± 0.04a3 45.35 0.71 ± 0.03a3 36.61
Control 0.78 ± 0.08 —————— 1.02 ± 0.07 ——————
CF 200 0.61 ± 0.07b1 21.79 0.85 ± 0.07b1 16.67
CF 300 0.53 ± 0.04a1 32.05 0.75 ± 0.04a1 26.47
CF 400 0.48 ± 0.04a2 38.46 0.69 ± 0.03a2 32.35
Loperamide 3 0.43 ± 0.06a2 44.87 0.66 ± 0.05a3 35.29
Control 0.83 ± 0.06 ——— 1.10 ± 0.03 —————
MF 200 0.67 ± 0.04b1 19.28 0.93 ± 0.07b1 15.45
MF 300 0.58 ± 0.03a1 30.12 0.81 ± 0.04a1 26.36
MF 400 0.49 ± 0.08a2 40.96 0.73 ± 0.08a2 33.64
Loperamide 3 0.47 ± 0.04a3 43.47 0.68 ± 0.02a3 38.18
Control 0.83 ± 0.06 ———— 1.10 ± 0.03 —————
AF 200 0.76 ± 0.04b2g1j1n1 8.43 1.02 ± 0.05b3g2j2n1 8.18
AF 300 0.73 ± 0.07b1j1n1 12.05 0.98 ± 0.07b2g1j1 10.91
AF 400 0.68 ± 0.07 18.07 0.93 ± 0.05b1 15.45
AF 800 0.55 ± 0.02a2 33.74 0.76 ± 0.03a2 30.90
Loperamide 0.47 ± 0.04a3 43.47 0.68 ± 0.02a3 38.18
Values are mean ± SEM (n = 6); analysis was performed using one way ANOVA followed by Tuckey post hoc test; a compared with control values; b compared with
loperamide; c compared with 100 mg/kg; d compared with 200 mg/kg; ecompared with 300 mg/kg; f compared with 400 mg/kg; g compared with 800 mg/kg,
h compared with CF200, i compared with CF300, j compared with CF400, kcompared with MF200, m compared with MF 300, n compared with MF 400; 1p < 0.05,
2p < 0.01, 3p < 0.001; 80ME = 80% methanol extract, CF = chloroform fraction, MF =methanol fraction, AF = aqueous fraction. Controls are 10 ml/kg- distilled water
(for 80ME, MF and AF) and 2% Tween-80 (for CF)
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increase gastrointestinal motility, net secretion of water
and electrolytes [24, 33].
CO induced diarrheal model was designed to assess
the potential of a test substance in its overall antidiar-
rheal activities. The onset of defecation, the frequency
and weight of fecal outputs were determined as the main
parameters. The 80ME (middle and higher doses) signifi-
cantly delayed the initiation of diarrhea and reduced the
number and weight of both wet and total fecal outputs
with the highest effects observed at later dose. Diarrhea
is characterized by fecal urgency and incontinence [34,
35]. Substances exhibiting significant antidiarrheal activ-
ity may have a potential to retard the onset of diarrhea
as observed at 200 and 400 mg/kg 80ME. Even though
diarrhea has been defined over time by various scientific
groups and organizations in different ways, greater em-
phasis is given on the consistency of stools than the fre-
quency [35]. Therefore, determination of the percentage
inhibition has been based on the reduction of frequency
of wet fecal outputs as a good marker of antidiarrheal
activity. Diarrhea is also presented with an increase in
weight of defecation [35, 36]. Accordingly, the 80ME
displayed a dose-dependent reduction in weight of fecal
outputs indicating the antidiarrheal potential of the
80ME in this model.
Coming to the solvent fractions, both the CF and MF
(at 400 mg/kg) produced significant effects in all pa-
rameters in this model. In addition, both of these frac-
tions significantly decreased the frequency of wet feces
and weight of both wet and total stools at 300 mg/kg.
Generally, these fractions had comparable antidiarrheal
effects but the effects were lower than that of the
80ME. Looking at the dose dependency nature of the
fractions, the MF (R2 = 0.994) appeared to have a
steeper slope than the CF (R2 = 0.980). This might be
Table 4 In vivo antidiarrheal indices of 80ME and solvent fractions of the leaves of Myrtus communis
Dose (mg/kg) Delay in defecation
(time of onset in min, Dfreq) (%)
Gut meal travel distance
(Gmeq) (%)
Purging frequency in
number of wet stools (%)
In vivo antidiarrheal
index (ADI)
Control ————— ————— ————— —————
80ME 100 43.04 33.54 42.58 39.47
80ME 200 89.12 46.12 62.52 63.58
80ME 400 126.72 62.31 74.96 83.96
Loperamide 3 110.64 59.61 72.56 78.22
Control ————— ———— ———— ———
CF 200 53.84 27.99 38.46 38.69
CF 300 75.25 35.11 51.23 51.34
CF 400 89.59 44.86 58.92 61.87
Loperamide 3 106.85 60.56 74.31 78.34
Control ———— ———— ———— ————
MF 200 50.48 21.24 31.07 32.18
MF 300 96.16 35.85 48.93 55.25
MF 400 124.29 47.54 62.67 71.81
Loperamide 3 140.63 61.47 75.56 86.76
Control ————— ————— —————— —————
AF 200 2.16 4.81 8.93 4.53
AF 300 11.54 12.58 15.60 13.13
AF 400 16.83 20.73 24.40 20.42
AF 800 94.24 38.61 53.33 57.89
loperamide 140.63 61.47 75.56 86.76
80ME = 80% methanol extract, CF = chloroform fraction, MF =methanol fraction, AF = aqueous fraction
Table 5 Preliminary phytochemical screening of the 80%
methanol extract and solvent fractions of the leaves of Myrtus
communis L
Constituents Crude extract Solvent fraction
80ME Chloroform Methanol Aqueous
Cardiac glycosides + _ + +
Flavonoids + + + -
Alkaloids _ _ _ _
Saponins + _ + +
Steroids _ + _ _
Tannins + + + +
Terpenoids + + + _
+ = present; − = Absent
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attributed to qualitative and quantitative differences in
bioactive constituents of these fractions. On the con-
trary, the aqueous fraction was devoid of any significant
delay in onset of diarrhea at all tested doses. This study
was in line with other studies where the CF and MF of
medicinal plants reduced the frequency and weight of
stools [37, 38].
Non-steroidal anti-inflammatory drugs (NSAIDs) could
inhibit castor oil induced diarrhea [39]. Similarly, 80%
ethanolic extracts of Myrtus communis L. showed potent
anti-inflammatory activity in a previous study [40]. This
was further supported by the fact that isolated constitu-
ents from the leaves of this plant are known to suppress
the biosynthesis of eicosanoids both in vivo and in vitro
[41]. Certain flavonoids, tannins and terpenoids re-
vealed antidiarrheal activities via a multitude of mecha-
nisms [42–44]. Most of the aforementioned secondary
metabolites were screened from the leaves of this plant
so far [45].
The reduction of gastrointestinal motility is one of the
mechanisms by which antidiarrheal agents can act [46].
It was observed that the 80ME significantly suppressed
the propulsion of charcoal marker at all tested doses.
This finding suggests that this extract has the ability to
influence the peristaltic movement of intestine thereby
indicating the presence of an antimotility activity.
Besides, both the CF and MF had comparable antispas-
modic effects with the highest effect revealed at
400 mg/kg of MF (47.54%, p < 0.001). Previous study
on isolated tissue preparations demonstrated that 70%
methanolic extract of Myrtus communis L.leaf pos-
sessed bronchodilator, spasmolytic and vasodilator
activities [14]. Therefore, it is plausible to assume that
the in vivo antimotility effect of the 80ME and solvent
fractions could be partly ascribed to such in vitro ef-
fects. It is in line with related studies where in vitro
mechanistic studies were correlated with in vivo anti-
motility activities [47, 48].
The third being enteropooling model was aimed to as-
sess the secretary components of diarrhea. In this model,
the 80ME extract showed significant reduction in both
AVIC and AWIC at all tested doses as compared to con-
trol. Besides, both the CF and MF showed comparable
percent reduction of both AVIC and AWIC at all tested
doses. On the contrary, the AF was devoid of significant
inhibition of intestinal fluid accumulation up to 400 mg/
kg. Mascolo et al. reported that the active metabolite,
ricinoleic acid might activate the nitric oxide pathway
and induce nitric oxide (NO) dependent gut secretion
[49]. A growing body of evidence indicated that phyto-
chemical constituents such as terpenoids [50] and flavo-
noids [51] are implicated in attenuation of NO synthesis.
In contrast to the aqueous fraction, the significant anti-
secretory activities of the 80ME as well as the CF and
MF could probably be related to the existence and hence
synergistic effects of flavonoids, tannins and terpenoids.
Generally, the ADI value indicates a measure of how
much effective an extract is in treating diarrhea [25].
ADI was increased with dose suggesting the dose de-
pendency nature of the parameter. The 80ME showed
highest ADI value among all extracts with corresponding
doses reinforcing the notion that this extract is endowed
with better antidiarrheal activity compared to the solvent
fractions.
Interestingly, extensive studies revealed that the leaves
of Myrtus communis L. have shown promising anti-
microbial activities against several diarrhea causing path-
ogens [52–54]. Therefore, in addition to its antimotility
and antisecretory effects observed in this study, its over-
whelming antimicrobial properties reinforcing a notion
that Myrtus communis L. can possibly be a good candi-
date for diarrheas of diverse etiologies including those
with infectious component.
Conclusion
This study revealed that the 80ME and solvent fraction
of the leaves of Myrtus communis L. are endowed with a
promising antidiarrheal activity. Therefore, this finding
provides a scientific support for folkloric use of Myrtus
communis L. as antidiarrheal agent.
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